DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling

Aug 5, 2025Drug design, development and therapy

DHLCA may ease diabetic kidney disease by activating bile acid receptors and changing gut bacteria

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Plasma levels of dehydrolithocholic acid (DHLCA) were significantly lower in patients with (DKD) and macroalbuminuria compared to those with type 2 diabetes mellitus.

DHLCA levels showed a negative correlation with urine albumin and urine albumin-to-creatinine ratio.
In a mouse model of DKD, DHLCA administration significantly reduced urine albumin-to-creatinine ratio and fasting blood glucose levels.
DHLCA treatment improved liver function and reduced markers of kidney injury in DKD mice.
The treatment restored the expression of certain receptors () in kidney tissue.
Metagenomic analysis indicated changes in gut microbiota composition following DHLCA treatment.

AI simplified

PURPOSE: (DKD) is a major contributor to chronic kidney disease worldwide. (BAs) are increasingly recognized as key regulators of glucose metabolism and kidney function. This study aimed to investigate the role of BA metabolism in the progression of DKD.

METHODS: Plasma BA profiles were measured in healthy controls (HC), patients with type 2 diabetes mellitus (T2DM), and patients with DKD using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). After identifying potential BA biomarkers in the clinical cohort, in vivo validation was conducted using dehydrolithocholic acid (DHLCA) intervention in DKD mouse model. Kidney injury markers, as well as the expression of Takeda G protein-coupled receptor 5 (TGR5) and farnesoid X receptor (FXR), were evaluated. In addition, gut microbiota (GM) composition was analyzed via metagenomic sequencing following DHLCA treatment.

RESULTS: The plasma DHLCA levels were significantly lower in DKD with macroalbuminuria group compared to T2DM group and DKD with microalbuminuria group (< 0.01). Partial Spearman correlation analysis adjusted for age and diabetes duration showed that DHLCA levels were negatively correlated with urine albumin (= -0.347; 95% CI, -0.531 to -0.135; q = 0.008) and urine albumin-to-creatinine ratio (UACR) (= -0.332; 95% CI, -0.499 to -0.155; q = 0.010). In vivo, DHLCA administration significantly reduced UACR and fasting blood glucose (FBG) levels (< 0.01), and improved liver function (ALT,< 0.05) in DKD mice. DHLCA treatment attenuated renal tubular injury, restored expression in kidney tissue, and decreased levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Metagenomic analysis revealed an enrichment offollowing DHLCA treatment. P ρ ρ P P Lachnospiraceae bacterium

CONCLUSION: DHLCA may represent a promising therapeutic candidate for DKD by targeting the TGR5/FXR signaling pathway and GM remodeling. Its metabolic and kidney benefits, along with an improved hepatic profile and absence of hepatotoxicity, support further translational investigation.

Key numbers

< 0.01

Decrease in DHLCA Levels

DHLCA levels in with macroalbuminuria vs. T2DM and microalbuminuria groups.

< 0.01

Reduction in UACR

UACR levels in mice treated with DHLCA.

< 0.05

Improvement in ALT Levels

Comparison of ALT levels in mice treated with DHLCA vs. untreated.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗

DHLCA Alleviates Diabetic Kidney Disease via TGR5/FXR Activation and Gut Microbiota Remodeling

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief